Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study
Conditions : DLBCL Interventions : Drug: Minjuvi Sponsors : TTY Biopharm Active, not recruiting
Read the full article2d agoen
Comments
Sign in to join the conversation.
No comments yet. Be the first.